Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United States
Emory University, Atlanta, Georgia Massachusetts General Hospital, Boston, Massachusetts Japan
Kanazawa Medical University Hospital, Kahoku-gun, JP